Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DARE vs GNPX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

GNPX Captures Overall Composite Edge (42.2 HOLD vs 45.4 HOLD), While DARE Leads 3–1 on Growth & Valuation Pillars

GNPX Overall Winner 6-Pillar Tally: DARE 3 – 1 GNPX (2 Tie) Matrix Metrics: DARE 4 – 4 GNPX

As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.2/100 HOLD vs. 45.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.41 (1.3x Forward P/E, -746.1% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. GNPX 42.2/100 HOLD), GNPX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -746.1% operating margin) and revenue trajectory (+0.0% vs. +2005.6% YoY).
  • Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DARE vs GNPX
DARE NASDAQ
Dare Bioscience, Inc. Common Stock
Pharmaceutical Preparations
$0.41
-9.86% 1D
Market Cap $9.6M
TTM Revenue $1.4M
Forward P/E 1.3x
Beta / 30D Vol 1.59β · 112% Vol
Unified Composite Score
45.4 / 100 HOLD
Tech 40.0 Fund 46.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.0%), weak momentum, RSI 23
RSI-14: 23.4 · SMA20: $0.61 · SMA50: $0.70
GNPX NASDAQ Head-to-Head Winner
Genprex, Inc. Common Stock
Pharmaceutical Preparations
$1.45
-13.17% 1D
Market Cap $2.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -4.68β · 96% Vol
Unified Composite Score
42.2 / 100 HOLD
Tech 25.0 Fund 47.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -22.2%), weak momentum, RSI 27
RSI-14: 26.6 · SMA20: $2.00 · SMA50: $2.48

6-Pillar Scorecard Institutional Category Breakdown (DARE 3 – 1 GNPX)

Columns: Metric · DARE · GNPX
1. Valuation Multiples DARE
Forward P/E 1.3x N/M
Trailing P/E 1.3x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale DARE
Revenue Growth (YoY) +2005.6% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.4M N/A
Market Cap $9.6M $2.2M
3. Profitability & Quality GNPX
Gross Margin N/A N/A
Operating Margin -746.1% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -407.1% -233.7%
4. Balance Sheet & Cash Flow DARE
Cash Generation (TTM) -$12M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $12M Net Cash $11.26 Book/Sh · -233.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DARE (4) vs GNPX (4)
Institutional Metric DARE GNPX Criterion Row Edge
Market Capitalization
Scale
$9.6M $2.2M Larger Scale Tie
Trailing P/E Ratio
Valuation
1.3x N/M Lower Multiple DARE
Forward P/E Ratio
Valuation
1.3x N/M Lower Multiple DARE
Revenue Growth (YoY)
Growth
+2005.6% +0.0% Higher Growth DARE
Operating Margin (TTM)
Profitability
-746.1% 0.0% Higher Margin GNPX
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-407.1% -233.7% Higher ROE GNPX
52-Week Range Position
Momentum
0% ($0–$4) 11% ($0–$10) Stronger Trend GNPX
Beta / 30D Volatility
Risk Regime
1.59β · 112% Vol -4.68β · 96% Vol Lower Realized Risk GNPX
Unified Institutional Score
Composite Signal
45.4 / 100 (HOLD) 42.2 / 100 (HOLD) Higher Composite DARE
Trailing 12M Revenue (USD)
Operating Scale
$1.4M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($12M Net Cash) N/A ($11.26 Book/Sh · -233.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GNPX +10.72 pp
DARE: -37.49% · GNPX: -26.77%
3M Horizon DARE +14.76 pp
DARE: -49.17% · GNPX: -63.93%
6M Horizon GNPX +159.4 pp
DARE: -82.81% · GNPX: +76.59%
1Y Horizon GNPX +19.59 pp
DARE: -76.18% · GNPX: -56.59%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DARE vs GNPX. Trailing 12-month operating profitability (DARE -746.1% vs GNPX 0.0%) and valuation multiples (DARE 1.3x vs GNPX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

DARE ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.4M
Gross MarginN/A
Op. Margin-746.1%
ROE / Fwd P/E-407.1% · 1.3x
GNPX ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-233.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DARE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DARE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GNPX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GNPX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DARE Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.6M market capitalization and -746.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GNPX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ DARE vs GNPX Key Questions & Quantitative Answers

As of Nov 20, 2026, Genprex, Inc. (GNPX) captures the overall head-to-head institutional edge over Dare Bioscience, Inc. (DARE) on higher Unified Composite conviction (42.2/100 HOLD vs. 45.4/100 HOLD) after splitting the core matrix 4–4 (led by Profitability & Quality), while DARE wins 3–1 across the 6-pillar growth and valuation breakdown. DARE trades at $0.41 (1.3x Forward P/E, -746.1% operating margin) versus GNPX at $1.45 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While DARE currently prints a higher short-term Unified Composite Score (45.4/100 HOLD vs. GNPX 42.2/100 HOLD), GNPX captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -746.1% operating margin) and revenue trajectory (+0.0% vs. +2005.6% YoY). Technical & Structure Timing Caution: DARE is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 23.4); meanwhile GNPX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DARE leads the Growth & Scale pillar: DARE posts +2005.6% YoY revenue growth and +0.0% YoY earnings growth on $1.4M TTM revenue (N/A gross margin, -746.1% operating margin), compared with GNPX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, DARE generates $1.4M in USD-normalized revenue versus N/A for GNPX. In operating R&D and SG&A reinvestment, DARE deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GNPX.

DARE screens cheaper on headline valuation multiples. DARE trades at 1.3x Forward P/E, 1.3x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas GNPX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DARE (-407.1% ROE) versus GNPX (-233.7% ROE) capital efficiency.

In options market volatility and institutional positioning, DARE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.59β · 112% Vol realized risk). By comparison, GNPX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-4.68β · 96% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.